In April 2026, President Trump signed an executive order directing the federal government to study ibogaine as a treatment for veterans with PTSD — and days later, the FDA greenlit the first-ever human clinical trial of an ibogaine compound. These are historic milestones. But the story of ibogaine starts long before Washington got involved.

This is Part 1 of a two-part series. Here, we trace ibogaine from its roots in West African spiritual practice to the accidental discovery that changed everything. Read Part 2: The Breakthrough →

Roots in the Bwiti Tradition

Tabernanthe iboga is an evergreen shrub native to the rainforests of Gabon, the Democratic Republic of Congo, and Cameroon. For centuries — likely far longer than written records can confirm — the root bark of the iboga plant has been central to the Bwiti spiritual tradition, practiced among the Punu, Mitsogo, and Fang peoples of Gabon.

According to tradition, the Pygmy peoples first discovered iboga's effects after observing mountain gorillas chewing the root bark. At low doses, iboga acts as a stimulant — hunters reported covering longer distances, carrying heavier loads, and going days without sleep. At moderate to high doses, it produces vivid, dream-like visionary states that the Bwiti consider essential for communicating with ancestors and understanding one's place in the spiritual world.

The Bwiti initiation ceremony lasts 3-7 days and involves consuming large doses of iboga root bark under the guidance of an N'ganga (spiritual leader), accompanied by music, dance, fasting, and purification rituals. Today, Bwiti is one of three officially recognized religions in Gabon. The country has prohibited the exportation of iboga since 1994 to protect both the tradition and the increasingly threatened wild plant populations.

Western Science Takes Notice

French and Belgian explorers first documented iboga use in African ceremonies in the 19th century. French naval physician Marie-Théophile Griffon du Bellay recorded its use in Gabon, and the first formal botanical description of Tabernanthe iboga appeared in 1889.

In 1901, ibogaine — the primary psychoactive alkaloid in iboga root bark — was independently isolated by two research teams: Dybowski and Landrin, and Haller and Heckel. The complete chemical synthesis wouldn't come until 1966, accomplished by G. Büchi.

Between the 1930s and 1960s, ibogaine was sold commercially in France under the brand name Lambarène as a mental and physical stimulant. It gained popularity among athletes before France banned ibogaine-containing products in 1966.

The Accidental Discovery That Changed Everything

In 1962, a 19-year-old heroin addict from the Bronx named Howard Lotsof took ibogaine — not to treat his addiction, but recreationally. What happened next was unexpected: after the experience, he noticed his heroin cravings had vanished. His withdrawal symptoms were gone. Five of his friends, all heroin addicts, tried ibogaine and reported the same thing.

Lotsof had accidentally stumbled onto what would become the central promise of ibogaine: a single treatment that could interrupt opioid addiction.

It took Lotsof decades to get anyone to listen. He graduated from NYU with a film degree in 1976, but never stopped advocating for ibogaine research. In 1985, he was awarded U.S. Patent 4,499,096 for a "Rapid Method for Interrupting the Narcotic Addiction Syndrome" — the first patent for ibogaine's anti-addictive use. He filed his final patent in 1992, covering poly-drug dependency syndromes.

Lotsof contracted with a Belgian manufacturer to produce ibogaine capsules and conducted successful trials in the Netherlands with Dutch psychiatrist Jan Bastiaans. He founded NDA International to facilitate treatments and authored the Ibogaine Patients' Bill of Rights. Howard Lotsof died of liver cancer on January 31, 2010, at age 66 — never having seen ibogaine achieve the legal medical status he spent his life fighting for.

Scheduling and Suppression

In the late 1960s, the World Health Assembly classified ibogaine as "a substance likely to cause dependency or endanger human health." The United States placed ibogaine in Schedule I — the most restrictive category, alongside heroin and LSD — meaning it was officially classified as having high abuse potential, no accepted medical use, and no safe use even under medical supervision.

This effectively shut down legal research in the United States for decades.

Notably, ibogaine remains unscheduled under international UN drug treaties — which is why clinics in Mexico, Canada, the Bahamas, New Zealand, South Africa, Costa Rica, and Brazil have been able to operate legally or in regulatory gray areas.

The Research That Continued

Despite the US scheduling, preclinical research produced compelling results:

  • 1988: First placebo-controlled evidence that ibogaine reduces opioid withdrawal in animal models (Dzoljic et al.)
  • 1991: Stanley Glick's animal studies showed ibogaine reduced morphine self-administration
  • 1993: Effects on cocaine self-administration demonstrated (Cappendijk et al.)
  • 1995: Effects on alcohol dependence shown (Rezvani)

In the early 1990s, the National Institute on Drug Abuse (NIDA) began funding clinical studies. But in 1995, after the unexpected death of a female participant, NIDA terminated the project. In 1999, Kenneth Alper published data on 33 patients treated with ibogaine — 25 showed resolution of withdrawal symptoms, but one died after receiving the highest dosage.

Dr. Deborah Mash, a neuroscience professor at the University of Miami, became one of the most prominent ibogaine researchers. Using lower oral doses (10-12 mg/kg), her team treated 27 patients with more favorable results. She later founded DemeRx, a pharmaceutical company developing noribogaine — ibogaine's primary metabolite — as a potentially safer, more controlled compound for addiction treatment.

The Safety Question

Ibogaine is not without risk. A 2022 review documented 58 ibogaine-associated emergencies, including 38 deaths, with two fatalities occurring during formal clinical studies. The primary danger is QT prolongation — ibogaine can extend the heart's electrical cycle, potentially triggering fatal cardiac arrhythmias.

This cardiac risk is why modern ibogaine protocols emphasize pre-treatment EKG screening, medical supervision during treatment, and exclusion of patients with pre-existing heart conditions. It's also why the search for safer alternatives — like noribogaine and 18-methoxycoronaridine (18-MC) — continues alongside research on ibogaine itself.

The Underground Movement

While the US government debated, people were dying. As the opioid epidemic accelerated through the 2000s and 2010s, a network of underground and semi-legal ibogaine treatment clinics emerged — primarily in Mexico, Costa Rica, and the Bahamas. Thousands of people, many of them desperate opioid addicts who had failed every conventional treatment, traveled to these clinics for ibogaine therapy.

Some found life-changing relief. Some didn't. And some never came home. The lack of regulation meant wildly inconsistent safety protocols, unlicensed providers, and no standardized dosing. The very prohibition that was supposed to protect people was, in many cases, making ibogaine treatment more dangerous — not less.

In Part 2, we cover the breakthrough: the Stanford study that changed the conversation, the executive order, the FDA's first clinical trial, and what ibogaine's trajectory means for the broader botanical medicine movement. Read Part 2 →

This article is for educational purposes only. Favor'd Alkz does not sell, distribute, or advocate for ibogaine products. We cover this topic because the regulatory and scientific journey of botanical compounds — from traditional use to modern research to responsible regulation — is central to our industry and our values.